At the Oncidium foundation, we help people around the world access and understand Targeted Radionuclide Therapy (TRT) for cancer care.
Whether your medical team has already mentioned this therapy or you simply want to learn more, we hope this section gives you what you are looking for.
Click on any of the sections below to find out more.
Targeted Radionuclide Therapy (TRT) is a type of cancer treatment. It uses a small amount of a radioactive medicine that travels through your body and attaches to dedicated cancer cells. Once attached, it delivers radiation right where it is needed, while trying to spare healthy tissue as much as possible.
You may also hear Targeted Radionuclide Therapy (TRT) referred to as PRRT or Peptide Receptor Radionuclide Therapy, RLT or Radioligand Therapy, Radiopharmaceutical, Radiotheranostics or Molecular Radiotherapy or by specific treatment names such as Lutetium-177 DOTATATE, or Lutetium-177 PSMA
This field is newer and fast-moving. Different hospitals, countries, and research groups developed their own terms before the field agreed on a common language.
At the Oncidium foundation, we align with expert guidance. Nuclear medicine experts have now agreed on Targeted Radionuclide Therapy (TRT) as the shared term, and it is the one we use throughout this section of the website.
The drug contains what is called a ligand, a targeting molecule that acts like a key: it’s designed to find and stick to the right “lock” (the biological target) on the cancerous cell’s surface.
Its role is to guide both diagnosis and treatment to the cancer cells, by identifying what makes these cells different from normal ones.
A diagnostic radioligand tracer is administered by intravenous injection, followed a few hours later by a functional imaging scan.
The scans that are used are PET (positron emission tomography) and SPECT (single-photon emission computed tomography) scans. They are special types of imaging that use small amounts of radioactive material to show how tissues and tumors are working.
Unlike standard scans such as CT or MRI, which mainly show the body’s structure, these scans can confirm whether the tumor shows high “uptake” (meaning the tracer binds well to the cancer cells); if so, the patient may be considered a suitable candidate for the therapy.
If the scan confirms uptake and that the patient is considered as a suitable candidate for the therapy, the same vector is used again, this time carrying a different radioactive component. Its role is to deliver treatment directly to the cancer cells, helping to destroy them while minimizing exposure to most healthy tissues.
Radioligand Therapy is already used to treat several types of cancer.
Learn how effective it is and how it works for each specific cancer.
With over 950 therapy centers worldwide, this interactive global map is designed to help you find where radionuclide therapies are available. Explore the map to locate specialized centers providing these advanced treatments.
RTL-connect: A global treatment program for patients in financial need.
RLT- Connect is a collaborative platform established by the Oncidium foundation to facilitate access to Targeted Radionuclide Therapy (TRT) for cancer patients who cannot afford it, as the treatment is not yet reimbursed.
At the Oncidium foundation, we believe clinical trials open the door to tomorrow's cancer therapies.
We provide people living with cancer with the latest information on radiotheranostics and guide them to treatment centers and clinical studies that match their diagnosis.
By connecting patients with these state-of-the-art trials, we help advance new breakthroughs and ensure they can access the very best care options available.
Discover inspiring stories of people living with cancer and learn about radioligand therapy is helping them regain control over their lives.
